This site is intended for healthcare professionals

Chiesi establishes Boston unit to support treatments for rare lysosomal storage, hematological and ophthalmological disorders in the US.

Read time: 1 mins
Published:16th Feb 2020
Chiesi Farmaceutici has established a rare disease unit in Boston. The division will develop treatments for patients with rare lysosomal storage, hematological and ophthalmological disorders. Chiesi has built up a portfolio of rare disease assets and prospects in recent years. Chiesi already sells drugs against lysosomal storage disorders ,alpha?mannosidosis and nephropathic cystinosis outside the U.S. In 2018, Chiesi positioned itself to expand its rare disease activities into the U.S. by acquiring the rights to Protalix BioTherapeutics’ Fabry disease drug in the US. Chiesi sees the unit as a way to support development of rare disease drugs, with an initial focus on lysosomal storage disorders, hematology and ophthalmology.
Condition: Fabry Disease
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.